Table 1.

Demographic and clinical characteristics of CML patients in study cohorts 1 and 3 at study entry

Patient characteristics, mean (SD)	Cohort 1, n = 35		Cohort 3, n = 152
Age, y	52.7 (13.8)		51.1 (13.6)
Education level, y	14.7 (1.90)		14.7 (2.3)
Time since diagnosis, mo	70.8 (64.8)		72.5 (56.4)
Patient characteristics, no. (%)
Sex
Men	16 (46)		71 (47)
Women	19 (54)		81 (53)
Race and ethnicity
Hispanic, black non-Hispanic, Asian, and Native American	6 (17)		37 (24)
White non-Hispanic	29 (83)		115 (76)
Marital status
Married	27 (77)		115 (76)
Not married	8 (23)		37 (24)
Employment status
Employed outside the home	20 (57)		91 (60)
Not employed	15 (43)		61 (40)
ECOG PS score
Good (1 or lower)	34 (97)		149 (98)
Poor (2 or higher)	1 (3)		3 (2)
CML phase
Chronic phase	32 (91)		148 (97)
Accelerated phase	1 (3)		1 (1)
Blast crisis	2 (6)		3 (2)
Disease response
Hematologic	34 (97)		131 (86)
Complete cytogenetic	26 (74)		131 (86)
Complete or major molecular	60 (21)		53 (80)
Previous therapy
Yes	28 (80)		116 (76)
No	7 (20)		36 (24)
Treatment	Previous	Current	Previous	Current
Imatinib	23 (66)	7 (20)	57 (38)	71 (47)
Dasatinib	6 (17)	16 (46)	13 (9)	34 (22)
Nilotinib	4 (11)	4 (11)	9 (6)	22 (14)
Bosutinib	5 (14)	1 (3)	4 (3)	6 (4)
Ponatinib	0	3 (8)	0	5 (3)
Bafetinib	1 (3)	1 (3)	0	1 (1)
Rebastinib	0	1 (3)	0	3 (2)
Other drug therapy	22 (63)	1 (3)	88 (58)	3 (2)
HSCT in last 3 mo	5 (14)	0 (0)	7 (5)	1 (1)
No treatment	0	1 (3)	0	7 (5)

HSCT, hematopoietic stem cell transplant.